| Migraine Disorders
Emgality vs Qulipta
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Emgality vs Qulipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQulipta has a higher rate of injection site reactions vs Emgality based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qulipta but not Emgality, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Emgality
Qulipta
At A Glance
SC injection
Monthly
CGRP antagonist
Oral
Daily
CGRP receptor antagonist
Indications
- Migraine Disorders
- Cluster Headache
- Migraine Disorders
Dosing
Migraine Disorders 240 mg loading dose (two consecutive SC injections of 120 mg each) once, followed by 120 mg SC monthly.
Cluster Headache 300 mg (three consecutive SC injections of 100 mg each) at the onset of the cluster period, then monthly until the end of the cluster period.
Migraine Disorders (episodic) 10 mg, 30 mg, or 60 mg taken once daily orally, with or without food.
Migraine Disorders (chronic) 60 mg taken once daily orally, with or without food.
Contraindications
- Serious hypersensitivity to galcanezumab-gnlm or any of the excipients
- History of hypersensitivity to atogepant or any of the components of QULIPTA (reactions have included anaphylaxis and dyspnea)
Adverse Reactions
Most common (>=2%) Injection site reactions
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Anaphylaxis, angioedema, rash, hypertension, Raynaud's phenomenon
Most common (>=4%) Nausea, constipation, fatigue/somnolence
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity (anaphylaxis, dyspnea, rash, pruritus, urticaria, facial edema), hypertension, Raynaud's phenomenon
Pharmacology
Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor; it is not metabolized by cytochrome P450 enzymes, making interactions with CYP substrates, inducers, or inhibitors unlikely.
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it blocks CGRP receptor signaling implicated in migraine pathophysiology and is indicated for preventive treatment of migraine in adults.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Emgality
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (10/12) · Qty limit (11/12)
Qulipta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Emgality
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (7/8) · Qty limit (8/8)
Qulipta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Emgality
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Qulipta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EmgalityView full Emgality profile
QuliptaView full Qulipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.